Data / Research funding / Cervical Cancer
Cervical Cancer: 347 NIH awards ($581.9M) to 155 organizations
347 NIH awards ($581.9M) in the NIH spending category Cervical Cancer, to 155 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
347 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Pediatric HIV/AIDS Cohort Study (PHACS) 2020 | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $71,153,847 | September 18, 2020 | July 31, 2026 | WILLIAMS, PAIGE L | reporter.nih.gov |
| OCTRI - Culturally sensitive model to improve cervical cancer screening uptake in Spanish-speaking and American Indian/Alaska Native communities | NIH | National Center for Advancing Translational Sciences | 2021 to 2025 | $43,274,051 | September 2, 2017 | July 31, 2026 | MORRIS, CYNTHIA D | reporter.nih.gov |
| FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS | NIH | National Cancer Institute | 2021 to 2025 | $29,487,084 | April 6, 2018 | September 15, 2026 | PORRAS, CAROLINA | reporter.nih.gov |
| Case Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $28,812,474 | August 1, 1997 | March 31, 2030 | SCHWARTZ, GARY K | reporter.nih.gov |
| Cancer Center Support Grant P30 | NIH | National Cancer Institute | 2021 to 2025 | $17,994,069 | July 1, 2002 | June 30, 2026 | LARA, PRIMO N. | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations | NIH | National Cancer Institute | 2021 to 2025 | $6,605,241 | September 12, 2019 | July 31, 2026 | PALEFSKY, JOEL MICHAEL | reporter.nih.gov |
| Comparative Modeling to Inform Cervical Cancer Control Policies | NIH | National Cancer Institute | 2021 to 2024 | $6,568,988 | September 8, 2020 | August 31, 2025 | KIM, JANE JOOYUN | reporter.nih.gov |
| Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS) | NIH | National Cancer Institute | 2021 to 2023 | $6,487,883 | April 10, 2018 | March 31, 2025 | HUGHES, AMY E | reporter.nih.gov |
| Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico | NIH | National Cancer Institute | 2021 to 2025 | $5,948,066 | September 20, 2019 | July 31, 2026 | ELLSWORTH, GRANT B. | reporter.nih.gov |
| CASCADE Coordinating Center | NIH | National Cancer Institute | 2022 to 2025 | $5,257,059 | September 7, 2022 | May 31, 2027 | SIMINSKI, SUZANNE M. | reporter.nih.gov |
| Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,585,446 | July 1, 2010 | June 30, 2027 | NAKAGAWA, MAYUMI | reporter.nih.gov |
| Conversational Agent to Improve Guideline Concordant Care for People with Cervical Cancer Screening Abnormalities | NIH | National Cancer Institute | 2025 | $3,277,279 | August 15, 2025 | July 31, 2029 | PERKINS, REBECCA BERNSTEIN | reporter.nih.gov |
| The AVANÇO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV | NIH | National Cancer Institute | 2023 to 2025 | $3,150,121 | August 1, 2023 | July 31, 2028 | SCHMELER, KATHLEEN | reporter.nih.gov |
| Advanced diffusion MRI for evaluating early response to radiation treatment in cervical cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,147,525 | April 1, 2021 | March 31, 2026 | RAKOW-PENNER, REBECCA ANN | reporter.nih.gov |
| Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection | NIH | National Cancer Institute | 2021 to 2025 | $3,131,524 | May 1, 2021 | April 30, 2027 | ANDROPHY, ELLIOT J. | reporter.nih.gov |
| Reducing cervical cancer screening disparities in Somali immigrant women through a primary care based HPV self-sampling intervention | NIH | National Cancer Institute | 2021 to 2025 | $3,130,772 | June 15, 2021 | May 31, 2027 | PRATT, REBEKAH J. | reporter.nih.gov |
| EXTENSION OF ESCUDDO FOLLOW-UP FROM FIVE YEARS TO 7.5 YEARS (REFERRED TO AS ESCUDDO-7) | NIH | National Cancer Institute | 2025 | $3,083,060 | March 26, 2025 | September 15, 2025 | reporter.nih.gov | |
| Towards Cervical cancer elimination: Implementation and scale-up of a single-visit, screen-and-treat approach with thermal ablation for sustainable cervical cancer prevention services in Kenya | NIH | National Cancer Institute | 2021 to 2025 | $3,033,113 | September 21, 2021 | August 31, 2026 | MUGO, NELLY RWAMBA | reporter.nih.gov |
| Thibang Diphatlha: Testing adaptive strategies to close the gap from cervical cancer diagnosis to treatment in Botswana | NIH | National Cancer Institute | 2022 to 2025 | $3,000,303 | September 6, 2022 | August 31, 2027 | GROVER, SURBHI | reporter.nih.gov |
| The Empilisweni Initiative - Advancing Implementation of Cervical Cancer Control | NIH | National Cancer Institute | 2023 to 2025 | $2,987,351 | September 19, 2023 | August 31, 2028 | CASTOR, DELIVETTE | reporter.nih.gov |
| Enhanced BReast and cErvical cAncer screening in Kenya THROUGH implementation science research and training (The BREAKTHROUGH Center) | NIH | National Cancer Institute | 2023 to 2025 | $2,931,308 | September 19, 2023 | August 31, 2028 | CHUNG, MICHAEL HOONBAE | reporter.nih.gov |
| Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening | NIH | National Cancer Institute | 2021 to 2025 | $2,851,879 | April 1, 2020 | November 30, 2025 | FANG, CAROLYN Y. | reporter.nih.gov |
| Determining how a Werner helicase (WRN) tumor suppressor complex regulates the human papillomavirus 16 life cycle | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,779,718 | June 1, 2021 | May 31, 2026 | MORGAN, IAIN | reporter.nih.gov |
| Leveraging HIV infrastructure to implement cervical cancer prevention in adolescent HIV clinics in Zambia | NIH | National Cancer Institute | 2022 to 2025 | $2,769,417 | September 6, 2022 | August 31, 2027 | HUNLETH, JEAN MARIE | reporter.nih.gov |
| ACCESS: Accelerating Cervical Cancer Elimination through the integration of Screen-and-treat Services | NIH | National Cancer Institute | 2022 to 2025 | $2,746,831 | September 7, 2022 | August 31, 2027 | AARONS, GREGORY | reporter.nih.gov |
| The CASCADE CLIMB: Cervical cancer prevention in women Living with HIV research Mobilization Base | NIH | National Cancer Institute | 2022 to 2025 | $2,713,815 | September 20, 2022 | May 31, 2027 | WINER, RACHEL L. | reporter.nih.gov |
| Cervical cancer screening after age 65 in the era of HPV testing: estimating benefits and harms of screening cessation and continuation | NIH | National Cancer Institute | 2022 to 2025 | $2,653,119 | August 1, 2022 | July 31, 2027 | SAWAYA, GEORGE F | reporter.nih.gov |
| West Africa Self-Sampling HPV Based Cervical Cancer Control Program (WA-SS-HCCP) for WLWHA: Barriers, challenges, and needs | NIH | National Cancer Institute | 2022 to 2025 | $2,566,495 | September 7, 2022 | August 31, 2027 | HOU, LIFANG | reporter.nih.gov |
| The HPV9-10 Trial: Early Initiation of HPV Vaccination | NIH | National Cancer Institute | 2021 to 2024 | $2,537,601 | May 1, 2020 | April 30, 2026 | KEMPE, ALLISON | reporter.nih.gov |
| A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection | NIH | National Cancer Institute | 2021 to 2025 | $2,485,991 | August 5, 2021 | July 31, 2026 | SKUBITZ, AMY PATRICE | reporter.nih.gov |
| The CHESS (Community, Home-based Education, Screening Services) Strategy to increase cervical cancer control access for HIV positive women in Nigeria | NIH | National Cancer Institute | 2022 to 2025 | $2,475,158 | September 1, 2022 | August 31, 2027 | FLOWERS, LISA C. | reporter.nih.gov |
| UNC CASCADE Network Research Base | NIH | National Cancer Institute | 2022 to 2025 | $2,460,562 | September 2, 2022 | May 31, 2027 | SMITH, JENNIFER SUSAN | reporter.nih.gov |
| Probe-based two photon microscopy for functional, label-free early cancer diagnosis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $2,433,782 | July 1, 2020 | April 30, 2026 | GEORGAKOUDI, IRENE | reporter.nih.gov |
| Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | NIH | National Cancer Institute | 2021 to 2023 | $2,399,998 | September 15, 2021 | May 31, 2025 | GUERRERO-PRESTON, RAFAEL | reporter.nih.gov |
| Mechanism of gamma-secretase action during HPV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,393,557 | March 24, 2020 | August 31, 2025 | TSAI, BILLY | reporter.nih.gov |
| T-cell activation and exhaustion in the HIV-positive female genital tract | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,342,907 | July 5, 2023 | May 31, 2026 | MCCLELLAND, RAYMOND SCOTT | reporter.nih.gov |
| Rapid motion-robust quantitative DCE-MRI for the assessment of gynecologic cancers | NIH | National Cancer Institute | 2021 to 2024 | $2,338,594 | September 22, 2020 | June 30, 2025 | OTAZO, RICARDO | reporter.nih.gov |
| Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE) | NIH | National Cancer Institute | 2022 to 2025 | $2,315,714 | April 1, 2022 | March 31, 2027 | CREMER, MIRIAM | reporter.nih.gov |
| Portable, low-cost cryotherapy system that does not require consumable cryogen gas for the treatment of cervical precancerous lesions | NIH | National Cancer Institute | 2024 to 2025 | $2,297,920 | September 1, 2024 | August 31, 2026 | CHANG, WEI-HSIANG | reporter.nih.gov |
| Development and Validation of an Artificial-Intelligence-enabled Portable Colposcopy Device for Optimizing Triage Alternatives for HPV-based Cervical Cancer Screening | NIH | National Cancer Institute | 2022 to 2025 | $2,280,935 | May 20, 2022 | April 30, 2027 | RAMANUJAM, NIRMALA | reporter.nih.gov |
| The Microbiome and Mucosal Immunity in Cervical Cancer Disparities | NIH | National Cancer Institute | 2022 to 2025 | $2,247,793 | April 25, 2022 | March 31, 2027 | BURGENER, ADAM | reporter.nih.gov |
| Investigations Into The Molecular Pathogenesis Of Cervical Glandular Neoplasias | NIH | National Cancer Institute | 2021 to 2024 | $2,242,414 | July 2, 2020 | June 30, 2025 | BURK, ROBERT D | reporter.nih.gov |
| Ethnicity and Nativity in Cancer - Latino & Asian Enclaves: The ENCLAVE Study | NIH | National Cancer Institute | 2021 to 2024 | $2,219,992 | April 1, 2020 | March 31, 2026 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Multiparametric Magnetic Resonance Imaging as a Novel Approach to Brachytherapy for Cervical Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,207,873 | March 1, 2020 | February 28, 2026 | VISWANATHAN, AKILA | reporter.nih.gov |
| The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia | NIH | National Cancer Institute | 2023 to 2025 | $2,188,094 | September 19, 2023 | August 31, 2028 | LIN, LILIE LEMING | reporter.nih.gov |
| A Novel, Low-Cost, Handheld, 3D Imaging System for Improved Screening of Cervical Neoplasia in Resource Limited Settings | NIH | National Cancer Institute | 2023 to 2024 | $2,158,876 | August 1, 2021 | August 31, 2025 | CARSON, JOSEPH | reporter.nih.gov |
| Low-cost mobile colposcopy and confocal imaging for global prevention of cervical cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,157,600 | August 1, 2020 | April 30, 2026 | RICHARDS-KORTUM, REBECCA R. | reporter.nih.gov |
| A Randomized Clinical Trial to Assess the Effectiveness of Ablative Treatments for Cervical Cancer Risk Reduction in HIV+ Women living in Mozambique | NIH | National Cancer Institute | 2022 to 2025 | $2,124,467 | May 12, 2020 | July 31, 2027 | SCHMELER, KATHLEEN | reporter.nih.gov |
| Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care | NIH | National Cancer Institute | 2022 to 2025 | $2,114,061 | May 1, 2022 | April 30, 2026 | LIU, CHANGCHUN | reporter.nih.gov |
| Real-world effectiveness of HPV vaccine in women living with HIV and its impact on cervical cancer screening accuracies | NIH | National Cancer Institute | 2023 to 2025 | $2,109,984 | May 1, 2023 | April 30, 2029 | MOSCICKI, ANNA-BARBARA | reporter.nih.gov |
| Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,085,056 | July 15, 2023 | December 31, 2027 | MILLER, SUZANNE M | reporter.nih.gov |
| PCOM2 - The Physician Communication Intervention, Version 2.0 | NIH | National Cancer Institute | 2022 to 2025 | $2,078,331 | January 15, 2022 | December 31, 2026 | O'LEARY, SEAN T | reporter.nih.gov |
| TOPIC TITLE: CANCER TREATMENT TECHNOLOGIES FOR LOW-RESOURCE SETTINGSPROJECT TITLE: PRV311: A STANDALONE, SAFE, EFFECTIVE, AND AFFORDABLE TREATMENT FO | NIH | National Cancer Institute | 2022 | $2,049,944 | September 15, 2022 | September 14, 2024 | GOLDBERG, MANIJEH | reporter.nih.gov |
| Automated Digital Imaging for Cervical Cancer Screening | NIH | National Cancer Institute | 2021 to 2024 | $2,017,495 | July 6, 2020 | March 12, 2025 | KUHN, LOUISE | reporter.nih.gov |
| Molecular Biology of Oncogenic Papillomaviruses | NIH | National Cancer Institute | 2021 to 2022 | $2,013,620 | January 1, 2016 | December 31, 2023 | HOWLEY, PETER M | reporter.nih.gov |
| Assessing Multilevel Influences on Guideline-Concordant Care and Cervical Cancer Outcomes: The ACHIEVE Study | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,004,149 | May 5, 2023 | November 30, 2027 | LLANOS, ADANA A. M. | reporter.nih.gov |
| A Hybrid Implementation-Effectiveness Trial of Game Changers for Cervical Cancer Prevention in Uganda | NIH | National Cancer Institute | 2023 to 2025 | $2,002,502 | August 8, 2023 | July 31, 2028 | WAGNER, GLENN JOHN | reporter.nih.gov |
| Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care | NIH | National Cancer Institute | 2022 to 2024 | $2,002,128 | September 1, 2022 | April 1, 2025 | PAASCHE-ORLOW, MICHAEL | reporter.nih.gov |
| SBIR PHASE II, TOPIC 431: AUTOMATIC TREATMENT PLANNING OF CERVICAL CANCER HIGH-DOSE RATE BRACHYTHERPAY FOR LOW-RESOURCE SETTINGS. | NIH | National Cancer Institute | 2024 | $2,000,000 | September 4, 2024 | September 3, 2026 | GHIMIRE, KANCHAN | reporter.nih.gov |
| PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling | NIH | National Cancer Institute | 2022 to 2023 | $1,997,669 | September 5, 2022 | August 31, 2025 | WANG, YOUXIANG | reporter.nih.gov |
| Validation of a lab-free low-cost screening test for prevention of cervical cancer: automated visual evaluation | NIH | National Cancer Institute | 2023 to 2025 | $1,996,573 | July 1, 2020 | August 31, 2026 | LEVITZ, DAVID | reporter.nih.gov |
| Innovations in cervical cancer diagnosis for low resource settings using advanced optical imaging and machine learning diagnostic algorithms. | NIH | National Cancer Institute | 2022 to 2023 | $1,994,001 | September 13, 2019 | June 30, 2025 | KRIEGER, MARLEE | reporter.nih.gov |
| Point of Care HPV 16/18/45 DNA Test for Cervical Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,988,443 | September 22, 2023 | February 28, 2026 | CHO, HYUNDAE | reporter.nih.gov |
| From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer | NIH | National Cancer Institute | 2023 to 2024 | $1,909,685 | May 1, 2023 | April 30, 2026 | RIETZ, ANNE | reporter.nih.gov |
| PREVENT - Practice-based Approaches to Promote HPV Vaccination | NIH | National Cancer Institute | 2023 to 2025 | $1,908,049 | May 15, 2023 | April 30, 2028 | KEPKA, DEANNA LEE | reporter.nih.gov |
| Enhancing the Effectiveness of Community Health Workers to Reduce Cervical Cancer Disparities in African American Women | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $1,871,752 | September 23, 2020 | June 30, 2026 | BILLINGS, DOUGLAS W | reporter.nih.gov |
| Acceptability and feasibility of combination treatment for cervical precancer among South Africa women living with HIV | NIH | National Cancer Institute | 2021 to 2024 | $1,863,953 | June 1, 2020 | May 31, 2026 | CHIBWESHA, CARLA J | reporter.nih.gov |
| Novel see and treat strategies for cervical cancer prevention in low-resource settings | NIH | National Cancer Institute | 2021 to 2023 | $1,857,474 | February 1, 2019 | January 31, 2024 | RAMANUJAM, NIRMALA | reporter.nih.gov |
| Adaptation and implementation of a patient navigation program for cervical cancer screening across contexts in Senegal | NIH | National Cancer Institute | 2022 to 2025 | $1,845,918 | April 1, 2022 | March 31, 2027 | DYKENS, JON ANDREW | reporter.nih.gov |
| Optimizing radiation therapy through the manipulation of glutamine metabolism | NIH | National Cancer Institute | 2022 to 2025 | $1,844,128 | September 16, 2014 | August 31, 2027 | SCHWARZ, JULIE KRISTINA | reporter.nih.gov |
| The role of the microbiome in HPV-associated cervical cancer in women with HIV | NIH | National Cancer Institute | 2021 to 2024 | $1,836,170 | May 6, 2020 | April 30, 2026 | UHLEMANN, ANNE-CATRIN | reporter.nih.gov |
| High-throughput Clinical Hyperpolarized 13C MRI | NIH | Office of the Director, National Institutes of Health | 2025 | $1,835,840 | August 1, 2025 | July 1, 2027 | TSAI, LEO LEE | reporter.nih.gov |
| Optimizing ablation of cervical precancer with ethyl cellulose ethanol to enable translation to women in low and middle-income countries | NIH | National Cancer Institute | 2023 to 2024 | $1,822,439 | September 14, 2020 | August 31, 2025 | CROUCH, BRIAN | reporter.nih.gov |
| The effectiveness, cost-effectiveness, and budget impact of interventions to improve the delivery of cervical cancer screening in Puerto Rico. | NIH | National Cancer Institute | 2023 to 2025 | $1,791,615 | September 19, 2023 | August 31, 2028 | ORTIZ, ANA PATRICIA | reporter.nih.gov |
| Elucidation of Integrator's Function | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,791,432 | August 1, 2010 | May 31, 2027 | SHIEKHATTAR, RAMIN | reporter.nih.gov |
| Tri-City Cervical Cancer Prevention Study among Women in the Justice System | NIH | National Cancer Institute | 2021 to 2023 | $1,784,962 | December 1, 2018 | November 30, 2024 | RAMASWAMY, MEGHA | reporter.nih.gov |
| Mouse modeling of HPV infection | NIH | National Cancer Institute | 2021 to 2023 | $1,759,688 | December 1, 2018 | November 30, 2024 | HUNG, CHIEN-FU | reporter.nih.gov |
| Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,732,492 | June 1, 2024 | May 31, 2027 | GUERRERO-PRESTON, RAFAEL | reporter.nih.gov |
| A novel, one stop, affordable, point of care and artificial intelligence supported system of screening, triage and treatment selection for cervical cancer and precancer in the LMICs | NIH | National Cancer Institute | 2023 to 2025 | $1,730,892 | August 15, 2023 | July 31, 2028 | BASU, PARTHA | reporter.nih.gov |
| Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,725,233 | April 1, 2019 | March 31, 2024 | WU, TZYY-CHOOU | reporter.nih.gov |
| A Randomized Controlled Trial of Mail-Self Stamped HPV Testing to Increase Cervical Cancer Screening Participation Among Minority/Underserved Women in an Integrated Safety Net Healthcare System | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $1,713,104 | April 16, 2019 | March 19, 2023 | MONTEALEGRE, JANE R | reporter.nih.gov |
| Self-Testing Options in the era of Primary HPV screening for cervical cancer: the STEP trial | NIH | National Cancer Institute | 2021 to 2023 | $1,711,156 | July 1, 2019 | December 31, 2024 | GREEN, BEVERLY BETH | reporter.nih.gov |
| Enlisting HPV integration events to illuminate drivers and target treatment in invasive cervical cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,681,974 | July 15, 2022 | June 30, 2027 | RADER, JANET S. | reporter.nih.gov |
| High-risk HPV E6: dysregulation of immortalization, growth, and differentiation through protein partnerships in HPV-associated cancers | NIH | National Cancer Institute | 2021 to 2024 | $1,677,482 | June 4, 2014 | May 31, 2026 | KATZENELLENBOGEN, RACHEL ADRIA | reporter.nih.gov |
| Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation | NIH | National Cancer Institute | 2023 to 2025 | $1,661,015 | July 1, 2023 | June 30, 2026 | ZAMARIN, DMITRIY | reporter.nih.gov |
| Effectiveness of the HPV Vaccine in Immunocompromised Populations | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,654,519 | July 9, 2024 | May 31, 2029 | SILVERBERG, MICHAEL J | reporter.nih.gov |
| Rapid Point of Care Detection of HPV-Associated Malignancies | NIH | National Cancer Institute | 2021 to 2022 | $1,645,226 | May 12, 2017 | August 31, 2024 | ANDERSON, KAREN SUE | reporter.nih.gov |
| Evaluation of the Teal self-collect device for cervical cancer screening | NIH | National Cancer Institute | 2024 to 2025 | $1,628,469 | September 23, 2024 | August 31, 2026 | DEPEL, TRENA | reporter.nih.gov |
| Implementing and Evaluating the Cancer Tracking System (CATSystem): A systems level intervention to improve Cervical Cancer screening, treatment referral and follow up in Kenya | NIH | National Cancer Institute | 2023 to 2025 | $1,625,961 | August 15, 2023 | June 30, 2028 | KESSLER, SARAH FINOCCHARIO | reporter.nih.gov |
| Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach | NIH | National Cancer Institute | 2023 to 2025 | $1,622,893 | July 1, 2023 | June 30, 2028 | CASTRO, CESAR M | reporter.nih.gov |
| An integrated community-clinic model of optimized implementation strategies to increase early detection of breast and cervical cancers in Kenya | NIH | National Cancer Institute | 2023 to 2025 | $1,611,743 | February 1, 2023 | January 31, 2028 | SUBRAMANIAN, SUJHA | reporter.nih.gov |
| Human Papillomavirus Manipulation of Epithelial Differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,591,474 | May 14, 2020 | July 31, 2024 | WHITE, ELIZABETH A | reporter.nih.gov |
| Point-of-care screening test for early cervical cancer detection | NIH | National Cancer Institute | 2021 to 2024 | $1,575,268 | September 22, 2020 | June 30, 2026 | LINNES, JACQUELINE | reporter.nih.gov |
| Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,573,574 | January 12, 2018 | June 30, 2025 | CREMER, MIRIAM | reporter.nih.gov |
| Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers (PEER) | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,559,037 | August 28, 2024 | March 31, 2029 | PETRIK, AMANDA F. | reporter.nih.gov |
| Integrating multi-omics, imaging, and longitudinal data to predict radiation response in cervical cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,522,810 | September 7, 2023 | August 31, 2028 | ZHANG, JIN | reporter.nih.gov |
| Structural Studies of Human Papillomavirus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,515,049 | August 13, 2020 | July 31, 2023 | HAFENSTEIN, SUSAN | reporter.nih.gov |
| Renewal: HPV and the DNA Damage Response | NIH | National Cancer Institute | 2022 to 2025 | $1,501,000 | August 1, 2010 | June 30, 2027 | LAIMINS, LAIMONIS A. | reporter.nih.gov |
| HPV genomic structure in cervical cancer radiation response and recurrence detection | NIH | National Cancer Institute | 2023 to 2025 | $1,478,822 | May 1, 2023 | April 30, 2028 | ZHANG, JIN | reporter.nih.gov |
| Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24) | NIH | National Cancer Institute | 2022 to 2023 | $1,464,869 | April 15, 2018 | March 31, 2026 | LI, CHRISTOPHER I | reporter.nih.gov |
| Actions for Collaborative Community Engaged Strategies for HPV (ACCESS-HPV) | NIH | National Cancer Institute | 2023 to 2025 | $1,457,658 | September 22, 2022 | August 31, 2027 | IWELUNMOR, JULIET | reporter.nih.gov |
| Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub) | NIH | National Cancer Institute | 2024 to 2025 | $1,451,327 | September 20, 2022 | May 31, 2027 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| De-Implementation of Low-Value Cervical Cancer Screening | NIH | National Cancer Institute | 2022 to 2025 | $1,442,271 | August 1, 2022 | June 30, 2027 | RENDLE, KATHARINE A. | reporter.nih.gov |
| RepurPosed AntiretrOviraL ThErapieS to EliminAte Cervical Cancer (POLESA Trial) | NIH | National Cancer Institute | 2023 to 2025 | $1,440,319 | August 1, 2023 | July 31, 2028 | PINDER, LEEYA F | reporter.nih.gov |
| Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice (PREDICT) | NIH | National Cancer Institute | 2024 to 2025 | $1,423,644 | June 10, 2024 | May 31, 2026 | HAAS, JENNIFER S | reporter.nih.gov |
| Enhancing Primary Care Office Workflow to Prevent Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,417,156 | December 1, 2022 | May 31, 2028 | RAND, CYNTHIA M | reporter.nih.gov |
| Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub) | NIH | National Cancer Institute | 2022 to 2024 | $1,416,601 | September 20, 2022 | July 14, 2024 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| Secondary Cervical Cancer Prevention of Vulnerable Women with HPV and HIV Co-infection in India | NIH | National Cancer Institute | 2023 to 2025 | $1,393,110 | August 1, 2023 | July 31, 2029 | NYAMATHI, ADELINE M | reporter.nih.gov |
| Mouse Model of Human Papillomavirus Pathogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,386,914 | April 1, 2019 | March 31, 2025 | MUNGER, KARL | reporter.nih.gov |
| Addressing Cervical Cancer Disparities Among People Experiencing Homelessness | NIH | National Institute on Minority Health and Health Disparities | 2023 | $1,382,625 | September 1, 2023 | June 30, 2026 | RODRIGUEZ, NATALIA MARIA | reporter.nih.gov |
| Self-Testing for Cervical Cancer in Priority Populations: the STEP-2 Trial | NIH | National Cancer Institute | 2024 to 2025 | $1,356,980 | May 15, 2024 | April 30, 2026 | WINER, RACHEL L. | reporter.nih.gov |
| Baltimore CASCADE Study Site (BaCSS Project) | NIH | National Cancer Institute | 2023 to 2025 | $1,351,991 | September 15, 2023 | May 31, 2027 | ADEBAMOWO, CLEMENT ADEBAYO | reporter.nih.gov |
| Malawi Cancer Outcomes Research Program (M-CORP) | NIH | National Cancer Institute | 2021 to 2025 | $1,342,707 | June 1, 2021 | May 31, 2027 | FEDORIW, YURI | reporter.nih.gov |
| ARCHERY: Artificial Intelligence based Radiotherapy treatment planning for Cervical and Head and Neck cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,339,222 | September 1, 2022 | August 31, 2027 | AGGARWAL, AJAY | reporter.nih.gov |
| Automated Visual Evaluation for Cervical Cancer Screening in HIV-positive Women | NIH | National Cancer Institute | 2021 to 2024 | $1,331,744 | June 1, 2020 | May 31, 2026 | SAIDU, RAKIYA SAIDU | reporter.nih.gov |
| Role of the YAP1-LATS2 negative feedback loop in cervical carcinogenesis | NIH | National Cancer Institute | 2023 to 2025 | $1,315,399 | April 1, 2023 | March 31, 2028 | WANG, CHENG | reporter.nih.gov |
| Next Generation of HPV and Cervical Cancer Research in HIV+ Women | NIH | National Cancer Institute | 2021 to 2022 | $1,311,548 | July 11, 2018 | June 30, 2024 | STRICKLER, HOWARD D | reporter.nih.gov |
| Combined Imaging and RNA Analyses to Develop Cervical Cancer Biomarkers | NIH | National Cancer Institute | 2024 to 2025 | $1,309,803 | June 10, 2024 | May 31, 2029 | LI, HUA | reporter.nih.gov |
| Targeting tumoral Lactobacillus iners to improve outcomes in cervical cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,309,419 | July 1, 2024 | June 30, 2029 | COLBERT, LAUREN ELIZABETH | reporter.nih.gov |
| Promoting follow-up of abnormal cancer screening tests using population-basedsystems to support stepped care multilevel intervention | NIH | National Cancer Institute | 2021 to 2022 | $1,305,011 | September 30, 2018 | August 31, 2024 | HAAS, JENNIFER S | reporter.nih.gov |
| Implementation of Screen, Treat, and Triage for Women Living with HIV in La Romana (iSTAR) | NIH | National Cancer Institute | 2024 to 2025 | $1,301,571 | September 1, 2024 | August 31, 2029 | SCHNALL, REBECCA | reporter.nih.gov |
| Accelerated Brachytherapy Forward Chemoradiation Therapy (ABC-RT) for Cervical Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,270,410 | August 15, 2024 | July 31, 2029 | MARKOVINA, STEPHANIE | reporter.nih.gov |
| E7 TCR-T cell therapy for HPV-associated cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,269,979 | August 1, 2024 | July 31, 2028 | HINRICHS, CHRISTIAN | reporter.nih.gov |
| Advancing Cancer Control for Health and Value (ACCHV) | NIH | National Cancer Institute | 2024 to 2025 | $1,265,000 | June 1, 2024 | May 31, 2029 | MOUCHERAUD, CORRINA | reporter.nih.gov |
| Utilization of cervical cancer prevention tools and role of high-risk HPV type in the persistent cervical cancer disparities experienced by American Indian/Alaska Native women | NIH | National Cancer Institute | 2021 to 2025 | $1,257,642 | August 1, 2021 | July 31, 2026 | BRUEGL, AMANDA S | reporter.nih.gov |
| Structural Studies of Human Papillomavirus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,255,920 | August 13, 2020 | July 31, 2025 | HAFENSTEIN, SUSAN | reporter.nih.gov |
| Epidemiologic Impact of HPV Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,253,203 | January 18, 2013 | July 31, 2025 | DING, LILI | reporter.nih.gov |
| A hybrid type III effectiveness-implementation, pragmatic intervention trial for cervical cancer screen and treat in Mozambique | NIH | National Cancer Institute | 2024 to 2025 | $1,251,158 | September 1, 2024 | August 31, 2029 | MOON, D. TROY | reporter.nih.gov |
| Sexual Health Empowerment for Jail-Involved Women's Health Literacy and Prevention | NIH | National Cancer Institute | 2021 to 2023 | $1,249,946 | April 23, 2014 | March 31, 2025 | WICKLIFFE, JOI | reporter.nih.gov |
| Development, field testing and evaluation of the efficacy of a hand-held, portable and affordable thermo-coagulator to prevent cervical cancer in low- and middle-income countries | NIH | National Cancer Institute | 2021 to 2023 | $1,235,802 | July 7, 2016 | February 29, 2024 | BASU, PARTHA | reporter.nih.gov |
| The role of asymmetric protein dimethylation during the human papillomavirus lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,227,574 | June 7, 2022 | May 31, 2028 | VAN DOORSLAER, KOENRAAD | reporter.nih.gov |
| Strategies for Reaching and Impacting Our Communities Sustainably (NWP-ROCS Program) | NIH | National Cancer Institute | 2024 to 2025 | $1,221,356 | April 1, 2024 | March 31, 2029 | SHELTON, RACHEL C | reporter.nih.gov |
| Kupewa: Optimizing implementation strategies for cervical cancer prevention | NIH | National Cancer Institute | 2024 to 2025 | $1,199,376 | September 1, 2024 | August 31, 2029 | MOUCHERAUD, CORRINA | reporter.nih.gov |
| A Mobile Web App Intervention to Promote Cervical Cancer Screening among Indigenous Women | NIH | National Cancer Institute | 2024 to 2025 | $1,196,713 | September 1, 2024 | August 31, 2028 | ROH, SOONHEE | reporter.nih.gov |
| ENHANcing CErvical cancer screening and treatment in women LIviNg with HIV in KenyA (ENHANCE LINKAge) | NIH | National Cancer Institute | 2024 to 2025 | $1,188,915 | September 1, 2024 | August 31, 2029 | CHUNG, MICHAEL HOONBAE | reporter.nih.gov |
| Leveraging Project ECHO for improved cervical cancer screening in Ethiopia: An implementation study of integrated HPV selfsampling in HIV care centers | NIH | National Cancer Institute | 2024 to 2025 | $1,181,416 | August 15, 2024 | July 31, 2029 | LOTT, BREANNE | reporter.nih.gov |
| The role of SERPINB3 in cervical cancer therapeutic resistance | NIH | National Cancer Institute | 2024 to 2025 | $1,164,548 | April 1, 2024 | March 31, 2029 | MARKOVINA, STEPHANIE | reporter.nih.gov |
| Botswana CASCADE Clinical Trials Site | NIH | National Cancer Institute | 2022 to 2025 | $1,163,675 | September 5, 2022 | May 31, 2027 | DRYDEN-PETERSON, SCOTT | reporter.nih.gov |
| Molecular Markers for Tumors Associated with Extrachromosomal HPV | NIH | National Cancer Institute | 2024 to 2025 | $1,161,888 | March 5, 2024 | February 28, 2029 | OJESINA, AKINYEMI IFEDAPO | reporter.nih.gov |
| Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial | NIH | National Cancer Institute | 2023 to 2024 | $1,158,790 | September 18, 2020 | August 31, 2025 | LANDIER, WENDY | reporter.nih.gov |
| Georgia Consortium to Eliminate Cervical Cancer in Women Living with HIV (GaCECC-WLWH) | NIH | National Cancer Institute | 2023 to 2025 | $1,157,799 | August 15, 2023 | May 31, 2027 | FLOWERS, LISA C. | reporter.nih.gov |
| Translating Molecular Diagnostics for Cervical Cancer Prevention into Practice | NIH | National Cancer Institute | 2023 to 2025 | $1,151,104 | September 23, 2021 | August 31, 2027 | TRACY, J. KATHLEEN | reporter.nih.gov |
| Innovative Rapid Enabling, Affordable, point-of-Care HPV Self-Testing Strategy (I-REACH) | NIH | National Cancer Institute | 2023 to 2025 | $1,146,484 | September 1, 2023 | August 31, 2028 | IWELUNMOR, JULIET | reporter.nih.gov |
| Sample-to-answer HPV DNA nucleic acid test for cervical cancer screening in Mozambique | NIH | National Cancer Institute | 2024 to 2025 | $1,129,641 | September 1, 2024 | August 31, 2029 | RICHARDS-KORTUM, REBECCA R. | reporter.nih.gov |
| Multiplex In-Solution Protein Array (MISPA) for high throughput, quantitative, early profiling of pathogen-induced head and neck | NIH | National Cancer Institute | 2023 to 2025 | $1,125,628 | September 1, 2023 | August 31, 2026 | LABAER, JOSHUA | reporter.nih.gov |
| Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE) | NIH | National Cancer Institute | 2023 to 2025 | $1,121,797 | August 4, 2023 | May 31, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| Regulation of Human Papillomavirus Gene Expression | NIH | National Cancer Institute | 2021 to 2023 | $1,118,245 | September 30, 1993 | April 30, 2025 | LAIMINS, LAIMONIS A. | reporter.nih.gov |
| Increasing Cervical Cancer Screening Uptake Among Emergency Department Patients | NIH | National Cancer Institute | 2021 to 2023 | $1,112,568 | August 1, 2020 | April 30, 2025 | ADLER, DAVID H | reporter.nih.gov |
| Misoprostol to Optimize Prevention of Cancer of the Cervix: A Randomized Trial (MISOPCx Project) | NIH | National Cancer Institute | 2024 to 2025 | $1,112,361 | March 15, 2024 | February 28, 2029 | HUH, WARNER KING | reporter.nih.gov |
| Implementation of School-Entry Policies for Human Papillomavirus Vaccination | NIH | National Cancer Institute | 2021 to 2023 | $1,111,147 | December 1, 2018 | November 30, 2025 | COLON, VIVIAN | reporter.nih.gov |
| Development and clinical validation of a multi-type HPV E6/E7 oncoprotein test for cervical cancer screening and triage in low- and middle-income countries | NIH | National Cancer Institute | 2021 | $1,106,503 | June 1, 2016 | May 31, 2023 | ALMONTE, MARIBEL | reporter.nih.gov |
| Role of HIV in acceleration of HPV malignancy | NIH | National Cancer Institute | 2021 to 2023 | $1,100,905 | December 1, 2018 | November 30, 2024 | TUGIZOV, SHAROF M | reporter.nih.gov |
| POINT of CARE: PrOviding an Innovative New Triage and Treatment strategy for Cervical cAncer scReening Efficiency | NIH | National Cancer Institute | 2024 to 2025 | $1,090,015 | September 18, 2024 | August 31, 2029 | MASCH, RACHEL | reporter.nih.gov |
| Immediate early events of the HPV life cycle | NIH | National Cancer Institute | 2021 to 2025 | $1,066,434 | June 1, 2017 | March 31, 2029 | ZWOLINSKA, KATARZYNA | reporter.nih.gov |
| Pathogenic role of human papillomavirus (HPV) DNA Integration and clonal expansion in cervical tumorigenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,055,452 | September 9, 2022 | August 31, 2027 | VAN ARSDALE, ANNE | reporter.nih.gov |
| Epigenetic Regulation During the HPV Life Cycle | NIH | National Cancer Institute | 2021 to 2023 | $1,051,711 | December 6, 2018 | November 30, 2024 | MOODY, CARY A | reporter.nih.gov |
| Bi-directional regulation of chemokine receptor signaling | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,050,972 | September 1, 2021 | June 30, 2025 | MARCHESE, ADRIANO | reporter.nih.gov |
| Cervical Cancer Prevention Prebiotic Device | NIH | National Cancer Institute | 2025 | $1,039,382 | June 17, 2021 | August 31, 2027 | ELLINGTON, JOANNA ELIZABETH | reporter.nih.gov |
| The Impact of an Evidence-Based, Behavioral Cervical Cancer Screening Intervention among Women Living with HIV in Ghana (HOPE-inG): A Type 2 Hybrid Effectiveness Implementation Trial | NIH | National Cancer Institute | 2024 to 2025 | $1,033,253 | September 1, 2024 | August 31, 2029 | ASARE, MATTHEW | reporter.nih.gov |
| Evaluation of triage strategies and screening intervals in a human papillomavirus based cervical cancer screening program in women living with human immunodeficiency virus in Botswana | NIH | National Cancer Institute | 2022 to 2025 | $1,026,248 | July 1, 2022 | May 31, 2027 | LUCKETT, REBECCA | reporter.nih.gov |
| Strengthening epidermal defenses for the prevention of HPV infection and replication | NIH | National Cancer Institute | 2021 to 2023 | $1,017,436 | December 4, 2018 | November 30, 2023 | WELLS, SUSANNE I | reporter.nih.gov |
| HIV/cervical cancer cOntrol and Prevention clinical sitE in Kenya (HOPE-Kenya) | NIH | National Cancer Institute | 2022 to 2025 | $1,000,542 | September 8, 2022 | May 31, 2027 | CHUNG, MICHAEL HOONBAE | reporter.nih.gov |
| A first-in-class product for the clearance of high-risk human papillomaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,000,000 | December 17, 2024 | November 30, 2026 | THURMAN, ANDREA RIES | reporter.nih.gov |
| Liquid Immunotherapeutic Fiducial Eluter (LIFE) Gel for Cervical Cancer | NIH | National Cancer Institute | 2025 | $998,781 | September 24, 2025 | August 31, 2027 | KAKADE, SANDEEP | reporter.nih.gov |
| Mechanisms and Consequences of L2-Dependent Subcellular Trafficking of the HPV Genome. | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $995,818 | May 1, 2020 | April 30, 2024 | CAMPOS, SAMUEL K | reporter.nih.gov |
| Optimizing Efficiency and Quality of Brachytherapy for Cervical Cancer using Machine Learning Based Automation | NIH | National Cancer Institute | 2022 to 2025 | $992,811 | June 14, 2022 | August 31, 2025 | MEYERS, SANDRA MICHELLE | reporter.nih.gov |
| Improving HPV Vaccination Delivery in Pediatric Primary Care: The STOP-HPV Trial | NIH | National Cancer Institute | 2021 to 2022 | $991,895 | February 3, 2017 | January 31, 2024 | SZILAGYI, PETER G | reporter.nih.gov |
| Rwanda CASCADE Clinical Trials Site for cervical cancer prevention | NIH | National Cancer Institute | 2023 to 2025 | $928,400 | September 22, 2023 | May 31, 2027 | RUBAGUMYA, FIDEL | reporter.nih.gov |
| Chromosomal Instability as a Marker and Mechanism of Radiation Response | NIH | National Cancer Institute | 2021 to 2025 | $926,100 | July 1, 2021 | June 30, 2027 | COSPER, PIPPA F | reporter.nih.gov |
| Translating Molecular Diagnostics for Cervical Cancer Prevention into Practice | NIH | National Cancer Institute | 2021 to 2022 | $913,771 | September 23, 2021 | April 30, 2023 | TRACY, J. KATHLEEN | reporter.nih.gov |
| Early Oropharyngeal cancer and screening in Gay and Bisexual Men | NIH | National Cancer Institute | 2021 to 2022 | $894,702 | September 1, 2020 | March 19, 2025 | ROSS, MICHAEL W | reporter.nih.gov |
| Brown/Moi Training Program for the Prevention of HIV related Cervical Cancer | NIH | Fogarty International Center | 2021 to 2023 | $893,812 | April 16, 2019 | March 31, 2025 | CU-UVIN, SUSAN | reporter.nih.gov |
| THE CONTRACTOR SHALL MAINTAIN AND SUPPORT STUDY DATA INFRASTRUCTURE, DATA MANAGEMENT AND DATA PREPARATION, AND ADVANCED STATISTICAL AND BIOINFORMATICS | NIH | National Cancer Institute | 2021 to 2024 | $887,000 | September 23, 2022 | August 15, 2025 | GIFFEN, CAROL | reporter.nih.gov |
| Framing HPV Vaccination Messages for African American Parents | NIH | National Cancer Institute | 2021 to 2022 | $879,776 | February 13, 2018 | January 31, 2025 | NAN, XIAOLI | reporter.nih.gov |
| Rewiring of epigenetic DNA damage response pathways in HPV-induced cancer | NIH | National Cancer Institute | 2022 to 2025 | $876,840 | August 1, 2022 | July 31, 2026 | GOLDSTEIN, MICHAEL | reporter.nih.gov |
| Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Uganda (CASCADE UGANDA) | NIH | National Cancer Institute | 2022 to 2025 | $858,136 | September 8, 2022 | May 31, 2027 | MWESIGWA, BETTY | reporter.nih.gov |
| Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrence | NIH | National Cancer Institute | 2021 to 2023 | $853,605 | April 1, 2019 | March 31, 2025 | GROVER, SURBHI | reporter.nih.gov |
| Translational Use of Intradermal Needle-free Injector to facilitate and optimize global fractional dose HPV vaccine administration | NIH | National Cancer Institute | 2022 to 2023 | $843,564 | September 20, 2022 | May 17, 2024 | NATHALIE, LANDRY | reporter.nih.gov |
| RISE: Reducing Cancer and HIV Stigma through Empowerment | NIH | National Cancer Institute | 2025 | $825,966 | September 4, 2025 | August 31, 2030 | LU, QIAN | reporter.nih.gov |
| Human papillomavirus and risk to pregnancy: a cohort study | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $811,033 | September 4, 2025 | August 31, 2030 | BERENSON, ABBEY B | reporter.nih.gov |
| Multi-level shared decision-making intervention to prevent cancer in South Africa | NIH | National Cancer Institute | 2023 to 2025 | $803,688 | August 7, 2023 | July 31, 2026 | KATZ, INGRID T. | reporter.nih.gov |
| Integrated delivery of cancer control interventions for adolescents and young adults living with HIV in Zambia | NIH | National Cancer Institute | 2022 | $779,696 | September 2, 2022 | August 31, 2023 | SUBRAMANIAN, SUJHA | reporter.nih.gov |
| SEARCH: SMS Electronic Adolescent Reminders for Completion of HPV vaccination- Uganda | NIH | National Cancer Institute | 2023 to 2025 | $775,284 | August 1, 2020 | July 31, 2027 | STOCKWELL, MELISSA S | reporter.nih.gov |
| CAPRISA CASCADE Clinical Trials Network Clinical Research Site | NIH | National Cancer Institute | 2023 to 2025 | $773,000 | September 5, 2023 | May 31, 2027 | NAICKER, NIVASHNEE | reporter.nih.gov |
| KEMRI-PHRD UG1 CASCADE NETWORK UNIT: CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV RESEARCH | NIH | National Cancer Institute | 2023 to 2025 | $765,259 | September 19, 2023 | May 31, 2027 | MUGO, NELLY RWAMBA | reporter.nih.gov |
| Development of Systems and Education for Cervical Cancer prevention (DOSE-CC) | NIH | National Cancer Institute | 2025 | $753,446 | May 1, 2025 | April 30, 2030 | LUNZE, KARSTEN | reporter.nih.gov |
| STING Activating Synthetic Nanovaccine for HPV-Induced Cancers | NIH | National Cancer Institute | 2021 to 2022 | $745,327 | April 1, 2018 | March 31, 2024 | GAO, JINMING | reporter.nih.gov |
| Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24) | NIH | National Cancer Institute | 2021 | $743,093 | April 15, 2018 | March 31, 2022 | LI, CHRISTOPHER I | reporter.nih.gov |
| Global Infectious Diseases and HPV Research Training in Kenya | NIH | Fogarty International Center | 2021 to 2023 | $740,627 | August 3, 2018 | February 28, 2025 | TEMMERMAN, MARLEEN | reporter.nih.gov |
| Feasibility of artesunate to improve HPV and cervical precancer treatment outcomes among HIV positive women in LMICs | NIH | National Cancer Institute | 2023 to 2025 | $738,783 | September 6, 2023 | August 31, 2026 | MUNGO, CHEMTAI | reporter.nih.gov |
| Precision methylation biomarkers linked to cancer disparities | NIH | National Institute on Minority Health and Health Disparities | 2021 | $733,762 | September 24, 2019 | May 31, 2022 | GUERRERO-PRESTON, RAFAEL | reporter.nih.gov |
| Impact of intestinal helminth infection on HPV co-infection and the cervico-vaginal environment. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $719,355 | January 24, 2022 | December 31, 2026 | CLARK, EVA H | reporter.nih.gov |
| A stigma responsive service delivery model for HPV-based screening among women living with HIV | NIH | Fogarty International Center | 2022 to 2024 | $706,250 | July 20, 2022 | June 30, 2025 | HUCHKO, MEGAN J. | reporter.nih.gov |
| Expanded Safety and Preliminary Efficacy of Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women with HIV in Africa | NIH | National Cancer Institute | 2025 | $688,458 | September 15, 2025 | August 31, 2030 | MUNGO, CHEMTAI | reporter.nih.gov |
| Function and mechanism of EndoU | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $682,300 | September 15, 2024 | July 31, 2028 | KARGINOV, FEDOR V | reporter.nih.gov |
| Mechanisms of radiation-induced tumor cell death and survival in cervical cancer | NIH | National Cancer Institute | 2021 to 2023 | $677,374 | March 1, 2019 | February 28, 2025 | MARKOVINA, STEPHANIE | reporter.nih.gov |
| Small Compound Inhibitors Targeting HPV Genome Replication | NIH | National Cancer Institute | 2025 | $660,205 | December 1, 2024 | November 30, 2029 | CHIANG, CHENG-MING | reporter.nih.gov |
| Addressing HPV vaccination disparities through tailored messaging for hesitant families | NIH | National Cancer Institute | 2022 to 2024 | $659,697 | August 2, 2022 | April 1, 2025 | KOHLER, RACQUEL ELIZABETH | reporter.nih.gov |
| The impact of vaginal microbiota on cervical dendritic cells: an observational study of women from sub-Saharan Africa at high risk for HIV acquisition. | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $643,248 | April 15, 2020 | March 31, 2026 | SABO, MICHELLE CATHERINE | reporter.nih.gov |
| Strategies to Reduce Global Health Disparities in Cervical Cancer | NIH | National Cancer Institute | 2025 | $630,506 | January 1, 2025 | December 31, 2029 | WU, TZYY-CHOOU | reporter.nih.gov |
| Image-guided ethyl cellulose ethanol ablation to enable treatment of cervical dysplasia in low and middle-income countries | NIH | National Cancer Institute | 2025 | $627,148 | August 5, 2025 | July 31, 2030 | MUELLER, JENNA LYNNE HOOK | reporter.nih.gov |
| Promoting Cervical Cancer Screening among African American and Sub-Saharan African Immigrant women | NIH | National Cancer Institute | 2021 to 2024 | $613,712 | September 2, 2020 | August 31, 2025 | ADEGBOYEGA, ADEBOLA O | reporter.nih.gov |
| mSaada: A Mobile Health Tool to Improve Cervical Cancer Screening in western Kenya | NIH | National Cancer Institute | 2024 to 2025 | $571,834 | August 22, 2022 | August 31, 2027 | HUCHKO, MEGAN J. | reporter.nih.gov |
| Addressing emerging health system priorities in cervical cancer prevention: determining optimal strategies for human papillomavirus test-based screening and triage | NIH | National Cancer Institute | 2021 to 2022 | $571,828 | September 13, 2018 | August 31, 2024 | OGILVIE, GINA | reporter.nih.gov |
| Actions for Collaborative Community Engaged Strategies for HPV (ACCESS HPV) | NIH | National Cancer Institute | 2022 to 2023 | $566,887 | September 22, 2022 | September 2, 2023 | IWELUNMOR, JULIET | reporter.nih.gov |
| Remote Resilience: Novel Applications of mHealth in Nicaragua's Cancer Control Program | NIH | Fogarty International Center | 2024 to 2025 | $564,916 | August 12, 2022 | May 31, 2027 | MITCHELL, EMMA MCKIM | reporter.nih.gov |
| Developing therapeutic TCR mimic monoclonal antibodies for cancer | NIH | National Cancer Institute | 2022 to 2025 | $540,804 | September 1, 2022 | August 31, 2027 | DAO, TAO | reporter.nih.gov |
| Human papillomavirus regulation of the Hippo signaling pathway | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $533,707 | May 1, 2025 | April 30, 2030 | WHITE, ELIZABETH A | reporter.nih.gov |
| NCI Clinical Trial Research Strategy, Harnessing Innovation, and Implementation | NIH | National Cancer Institute | 2023 to 2025 | $521,760 | September 4, 2023 | August 31, 2028 | MAYADEV, JYOTI | reporter.nih.gov |
| A Technology-enhanced and Multilevel Approach to Promote Cervical Cancer Prevention Among Women Living with HIV | NIH | National Cancer Institute | 2023 to 2025 | $517,914 | September 15, 2023 | August 31, 2028 | LE, DAISY | reporter.nih.gov |
| Community-based Participatory Design of an HPV rapid diagnostic test for cervical cancer screening in South Florida | NIH | National Cancer Institute | 2021 to 2023 | $506,415 | September 20, 2019 | August 31, 2024 | RODRIGUEZ, NATALIA MARIA | reporter.nih.gov |
| University of California, Davis: Human Papillomavirus Cancer Free (UCD: HPV Cancer Free) | NIH | National Cancer Institute | 2023 to 2025 | $503,820 | September 1, 2023 | August 31, 2028 | DANG, JULIE | reporter.nih.gov |
| Identifying Novel Radiation Sensitizers in Cervical Cancer | NIH | National Cancer Institute | 2023 to 2024 | $499,316 | December 7, 2022 | November 30, 2025 | COLBERT, LAUREN ELIZABETH | reporter.nih.gov |
| Defining a globally accessible and pragmatic predictive signature (GAPPS) for locally advanced cervical cancer | NIH | National Cancer Institute | 2025 | $498,565 | September 8, 2025 | July 31, 2029 | KLOPP, ANN | reporter.nih.gov |
| Preventing Cervical Cancer in the First Mile of the Cancer Care Continuum | NIH | National Cancer Institute | 2021 to 2022 | $498,000 | September 8, 2020 | August 31, 2023 | MUELLER, JENNA LYNNE HOOK | reporter.nih.gov |
| Let’s K-Talk: A Storytelling Intervention Leveraging Chatbot Technology to Prevent HPV and HPV Associated Cancers for Ethnic Koreans Living in the U.S. | NIH | National Institute of Nursing Research | 2022 to 2024 | $489,666 | September 23, 2022 | July 31, 2025 | KIM, MINJIN | reporter.nih.gov |
| Obstetrical and Oncological Outcomes Among Reproductive Age Women with Gynecological and Breast Cancer | NIH | National Cancer Institute | 2021 to 2022 | $478,385 | September 18, 2018 | August 31, 2024 | RAUH-HAIN, JOSE ALEJANDRO | reporter.nih.gov |
| Development of Tailored, Multilevel Cervical Cancer Interventions for Ethnically Diverse Black Women | NIH | National Cancer Institute | 2024 | $477,869 | September 1, 2024 | August 31, 2027 | AMUTA, ANN OYARE | reporter.nih.gov |
| HPV alternative splicing in cervical cancer radiation response | NIH | National Cancer Institute | 2021 to 2023 | $459,514 | December 1, 2020 | November 30, 2023 | ZHANG, JIN | reporter.nih.gov |
| Cervical Cancer Prevention Prebiotic Device | NIH | National Cancer Institute | 2021 to 2022 | $454,968 | March 15, 2022 | June 14, 2022 | ELLINGTON, JOANNA ELIZABETH | reporter.nih.gov |
| Roles of p53-Regulated Pro-Survival Signals in Carcinogenesis by HTLV-1 and High-Risk Subtype HPVs | NIH | National Cancer Institute | 2023 | $445,500 | December 13, 2022 | November 30, 2025 | HARROD, ROBERT L. | reporter.nih.gov |
| A Delphi Study of Implementation Strategies for Cervical Cancer Control Policies in Africa | NIH | National Cancer Institute | 2025 | $442,750 | September 23, 2025 | August 31, 2027 | MOUCHERAUD, CORRINA | reporter.nih.gov |
| Genital Health of Trans-males on Testosterone | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $439,672 | March 15, 2021 | February 29, 2024 | GHOSH, MIMI | reporter.nih.gov |
| Global Hypomethylation Biomarkers for Cervical Cancer Screening in Women Living with HIV in LMICs | NIH | Fogarty International Center | 2021 to 2022 | $439,500 | August 16, 2021 | July 31, 2025 | ZHENG, YINAN | reporter.nih.gov |
| Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus | NIH | National Cancer Institute | 2022 | $437,203 | July 1, 2022 | March 31, 2025 | PARDHE, MARY | reporter.nih.gov |
| Development of a mouse model to test HPV Antiviral compounds | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $435,875 | November 7, 2022 | March 31, 2025 | ANDROPHY, ELLIOT J. | reporter.nih.gov |
| A co-infection model for papillomavirus associated infections and cancers | NIH | National Cancer Institute | 2023 to 2024 | $432,985 | April 1, 2023 | March 31, 2026 | HU, JIAFEN | reporter.nih.gov |
| Defining the ability of HPV oncogenes to promote mutagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $431,000 | July 27, 2023 | June 30, 2026 | WALLACE, NICHOLAS A | reporter.nih.gov |
| Increasing HPV vaccine uptake in community-based pediatric practices | NIH | National Cancer Institute | 2021 | $427,380 | December 20, 2016 | November 30, 2023 | HULL, PAMELA CARMEN | reporter.nih.gov |
| Gonococcal peptide vaccine candidate display using HPV virus-like particles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $422,872 | September 27, 2021 | August 31, 2023 | RAM, SANJAY | reporter.nih.gov |
| From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer | NIH | National Cancer Institute | 2022 | $420,989 | March 1, 2022 | April 30, 2023 | RIETZ, ANNE | reporter.nih.gov |
| Toward Racial Equity and Justice in Human Papillomavirus (HPV) Vaccination: An Exploratory Study with Cape Verdean Parents | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $419,375 | July 15, 2023 | January 31, 2026 | LINDSAY, ANA CRISTINA TERRA DE SOUZA | reporter.nih.gov |
| Point-of-care HPV mRNA test for cervical cancer screening in low-resource settings | NIH | National Cancer Institute | 2021 to 2022 | $418,211 | February 1, 2021 | January 31, 2023 | RICHARDS-KORTUM, REBECCA R. | reporter.nih.gov |
| Immunomodulatory effects of topical artesunate on cervical intraepithelial neoplasia 2/3. | NIH | National Cancer Institute | 2022 to 2023 | $417,215 | March 1, 2022 | December 28, 2024 | TRIMBLE, CORNELIA L | reporter.nih.gov |
| Evaluating scaleup of an adapted breast cancer early diagnosis program in Rwanda | NIH | National Cancer Institute | 2022 to 2023 | $409,103 | March 8, 2022 | February 28, 2025 | PACE, LYDIA | reporter.nih.gov |
| Cis-acting Elements in the Regulation of Papillomavirus Gene Expression | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $408,977 | November 18, 2022 | October 31, 2025 | VAN DOORSLAER, KOENRAAD | reporter.nih.gov |
| Deep learning in cervical cancer radiogenomics | NIH | National Cancer Institute | 2022 to 2023 | $401,291 | June 13, 2022 | May 31, 2024 | ZHANG, JIN | reporter.nih.gov |
| A low-cost topical immunotherapy formulation suitable for treating cervical cancer in low and middle income countries and low-resource settings in the U.S. | NIH | National Cancer Institute | 2021 | $400,000 | May 1, 2021 | April 30, 2023 | SHAMBLOTT, MICHAEL J | reporter.nih.gov |
| A Novel, Low-Cost, Handheld, 3D Imaging System for Improved Screening of Cervical Neoplasia in Resource Limited Settings | NIH | National Cancer Institute | 2021 | $400,000 | August 1, 2021 | July 31, 2022 | CARSON, JOSEPH | reporter.nih.gov |
| PHS 2022-1 TOPIC 440 - CANCER PREVENTION & DIAGNOSIS TECHNOLOGIES FOR LOW-RESOURCE SETTINGS | NIH | National Cancer Institute | 2022 | $400,000 | September 16, 2022 | September 15, 2023 | SCHOENBRUNNER, NANCY | reporter.nih.gov |
| PROJECT TITLE: AUTOMATIC TREATMENT PLANNING OF CERVICAL CANCER HIGH-DOSE RATE BRACHYTHERAPY FOR LOW-RESOURCE SETTINGS | NIH | National Cancer Institute | 2022 | $400,000 | September 15, 2022 | September 14, 2023 | LIANG, RON | reporter.nih.gov |
| Point of care diagnostic to improve access to gynecological screening in low-resource settings | NIH | National Cancer Institute | 2025 | $400,000 | September 1, 2025 | August 31, 2027 | CHRISTODOULIDES, NICOLAOS JOSEPH | reporter.nih.gov |
| Quantitative oxygen sensing to enable personalized oncology treatment planning | NIH | National Cancer Institute | 2021 | $399,740 | September 15, 2021 | February 28, 2025 | EKCHIAN, GREGORY | reporter.nih.gov |
| Highly stable mini-circRNA vaccine with maximally activated and long-lasting T cells for HPV-related cancer combination immunotherapy | NIH | National Cancer Institute | 2024 | $398,823 | August 1, 2024 | July 31, 2025 | PARRY, GORDON | reporter.nih.gov |
| SBIR PHASE I TOPIC 431, INTEGRATED CELL CULTURE CHAMBER AND FLOW GUIDE FOR POC, WALK-AWAY OPERATION FOR AUTOLOGOUS T CELL MANUFACTURING | NIH | National Cancer Institute | 2022 | $398,625 | September 15, 2022 | September 14, 2023 | MONTY, NATHAN | reporter.nih.gov |
| Detection of sentinel lymph nodes in female lower genital tract cancer patients with contrast-enhanced ultrasound imaging | NIH | National Cancer Institute | 2021 to 2022 | $397,469 | August 1, 2021 | July 31, 2024 | LIU, JI-BIN | reporter.nih.gov |
| Portable, low-cost cryotherapy system that does not require consumable cryogen gas for the treatment of cervical precancerous lesions | NIH | National Cancer Institute | 2022 | $396,587 | September 12, 2022 | February 29, 2024 | CHANG, WEI-HSIANG | reporter.nih.gov |
| COMParative ASSessment of p16/Ki-67 DUal Staining Technology in women living with HIV (COMPASS-DUST study) | NIH | Fogarty International Center | 2022 to 2025 | $395,913 | July 20, 2022 | June 30, 2027 | OKUNADE, KEHINDE SHARAFADEEN | reporter.nih.gov |
| The role of bacterial vaginosis-associated bacteria in papillomavirus persistence and cancers | NIH | National Cancer Institute | 2022 to 2023 | $393,218 | March 1, 2022 | February 28, 2025 | HU, JIAFEN | reporter.nih.gov |
| Antibody bound bacteria during HPV infection and cervical dysplasia | NIH | National Cancer Institute | 2024 to 2025 | $392,431 | August 8, 2024 | July 31, 2026 | LANGEL, STEPHANIE N. | reporter.nih.gov |
| Development and Characterization of Immunotherapies for HPV-Associated Malignancies | NIH | National Cancer Institute | 2021 to 2024 | $391,704 | September 1, 2020 | August 31, 2025 | PENG, SHIWEN | reporter.nih.gov |
| Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240 | NIH | National Cancer Institute | 2021 to 2022 | $391,222 | January 1, 2021 | December 31, 2023 | SECORD, ANGELES ALVAREZ | reporter.nih.gov |
| A RAPID ISOTHERMAL AMPLIFICATION CHIP FOR HPV DETECTION AND GENOTYPING IN LOW-RESOURCE SETTINGS | NIH | National Cancer Institute | 2022 | $389,973 | September 16, 2022 | September 15, 2023 | WONG, SEASON | reporter.nih.gov |
| The influence of tampon nanoplastic particles on gynecological mucosal barriers | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $386,440 | January 22, 2024 | December 31, 2026 | FOGG, KAITLIN C | reporter.nih.gov |
| HPV POINT OF CARE MOLECULAR DIAGNOSTICS FOR LMICS | NIH | National Cancer Institute | 2022 | $382,034 | September 16, 2022 | September 15, 2023 | MOUNZIH, KHALID | reporter.nih.gov |
| Investigating whether chlamydia trachomatis can increase the infectivity of HPV during genital tract infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $377,646 | March 10, 2023 | February 28, 2026 | DERBIGNY, WILBERT A | reporter.nih.gov |
| Combining c-Myc inhibitor and SHetA2 for cervical cancer: A promising low-to-no toxicity therapeutic strategy | NIH | National Cancer Institute | 2025 | $376,490 | July 1, 2025 | June 30, 2027 | RAI, RAJANI | reporter.nih.gov |
| A Topical Plasmid-based Approach to Cervical Cancer Screening | NIH | National Cancer Institute | 2024 to 2025 | $376,321 | March 1, 2024 | February 28, 2026 | WARRAM, JASON MORGAN | reporter.nih.gov |
| AI algorithm development for cervical cancer screening in low resource settings | NIH | National Cancer Institute | 2025 | $371,161 | September 1, 2025 | August 31, 2027 | KALPATHY-CRAMER, JAYASHREE | reporter.nih.gov |
| Remote Resilience: Novel Applications of mHealth in Nicaragua's Cancer Control Program | NIH | Fogarty International Center | 2022 to 2023 | $370,954 | August 12, 2022 | May 31, 2024 | MITCHELL, EMMA MCKIM | reporter.nih.gov |
| Identifying and Addressing Barriers in the Cervical Cancer Treatment Cascade among Women with HIV in South Africa | NIH | National Cancer Institute | 2024 | $368,070 | July 1, 2024 | June 30, 2026 | STANTON, AMELIA M. | reporter.nih.gov |
| Development of ablative therapy for the destruction of cervical neoplasia | NIH | National Cancer Institute | 2024 | $367,472 | September 1, 2024 | August 31, 2025 | SHIKHMAN, OLEG UNITED STATES | reporter.nih.gov |
| Elucidating the Role of the Vaginal Microbiome and Daily Stress in Precancerous Cervical Lesions: A Multi-level Study. | NIH | National Cancer Institute | 2024 to 2025 | $367,416 | July 1, 2024 | June 30, 2029 | TOSSAS, KATHERINE Y | reporter.nih.gov |
| Development of implementation toolkits to promote HPV self-sampling behavior among Women Living with HIV in Ghana | NIH | Fogarty International Center | 2024 to 2025 | $357,127 | April 1, 2024 | January 31, 2026 | ASARE, MATTHEW | reporter.nih.gov |
| Assess and Design a Multi-level Intervention with Middle to Older Age Mexican Immigrants to Increase Cervical Cancer Screening in Community Health Clinics | NIH | National Cancer Institute | 2024 to 2025 | $353,082 | August 1, 2024 | July 31, 2029 | VASQUEZ GUZMAN, CIRILA ESTELA | reporter.nih.gov |
| Characterizing Breast and Cervical Cancer Burden Among Sexual Minority women | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $352,368 | July 27, 2023 | February 29, 2028 | SPENCER, JENNY | reporter.nih.gov |
| mSaada: A Mobile Health Tool to Improve Cervical Cancer Screening in western Kenya | NIH | National Cancer Institute | 2022 to 2023 | $346,944 | August 22, 2022 | July 31, 2024 | HUCHKO, MEGAN J. | reporter.nih.gov |
| Improving cervical cancer prevention among women living with chronic conditions | NIH | National Cancer Institute | 2024 to 2025 | $343,850 | September 1, 2024 | August 31, 2029 | MKUU, RAHMA S | reporter.nih.gov |
| Harnessing Big Data to Identify Geographic Clusters of Low-income children with Poor HPV Vaccination Rates | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $343,172 | September 1, 2021 | May 31, 2025 | SONAWANE, KALYANI | reporter.nih.gov |
| Assessing how multilevel factors shape disparities in cancer screening | NIH | National Cancer Institute | 2023 to 2024 | $342,900 | February 1, 2023 | November 30, 2025 | DEL VECCHIO, NATALIE | reporter.nih.gov |
| Interventions to increase adherence to cervical cancer early detection and treatment recommendations in Mexico City clinics | NIH | National Cancer Institute | 2022 | $341,378 | September 22, 2022 | August 31, 2025 | SPIEGELMAN, DONNA L | reporter.nih.gov |
| Implementation and Impact of Cancer Screening Navigation by Community Health Workers in Two National Screening Programs | NIH | National Cancer Institute | 2021 to 2022 | $329,385 | September 15, 2018 | August 31, 2024 | BARRINGTON, WENDY ELIZABETH | reporter.nih.gov |
| Multicomponent mhealth interventions for healthcare providers and the community to increase cancer screening in India | NIH | National Cancer Institute | 2024 | $328,822 | September 20, 2024 | August 31, 2026 | SUBRAMANIAN, SUJHA | reporter.nih.gov |
| Development and validation of patient-ready Callascope for cervical imaging | NIH | National Cancer Institute | 2025 | $317,420 | July 1, 2025 | June 30, 2026 | CROUCH, BRIAN | reporter.nih.gov |
| A tailored, health communication intervention for HPV vaccine hesitant families | NIH | National Cancer Institute | 2021 to 2023 | $311,679 | June 1, 2020 | October 31, 2023 | ERVES, JENNIFER C. | reporter.nih.gov |
| Improving Routine Asymptomatic Cancer Screening among Federally Qualified Health Center Users in Florida: Application of a Health Literacy Framework | NIH | National Cancer Institute | 2021 to 2022 | $309,240 | April 1, 2018 | March 31, 2023 | BEST, ALICIA LYNETTE | reporter.nih.gov |
| Characterizing the role of cellular differentiation in productive papillomavirus amplification | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $307,000 | February 8, 2021 | January 31, 2024 | VAN DOORSLAER, KOENRAAD | reporter.nih.gov |
| Molecular Screening for Human Papilloma Virus (HPV) Associated with Cervical Cancers in LMIC Environments | NIH | National Cancer Institute | 2025 | $306,872 | September 1, 2025 | August 31, 2026 | NGUYEN, VI | reporter.nih.gov |
| The re-activatable Yb-169 radiation source: a therapeutic medical device to reduce the risk of brachytherapy and increase adoption | NIH | National Cancer Institute | 2022 | $300,000 | August 1, 2022 | July 31, 2025 | FLYNN, RYAN THOMAS | reporter.nih.gov |
| Small Molecule E6 Inhibitors to Treat Dysplasia Caused by HPV Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $298,527 | July 1, 2022 | March 31, 2024 | LU, ZHIJIAN | reporter.nih.gov |
| Novel Antimicrobial Approach to Treat Chemoradiation Resistant Cervical Cancer by Selectively Inhibiting Lactobacillus iners | NIH | National Cancer Institute | 2025 | $295,881 | May 20, 2025 | April 30, 2026 | LAGENAUR, LAUREL A. | reporter.nih.gov |
| A Health Disparities Visualization Tool for Informing Cancer Prevention and Control Efforts | NIH | National Library of Medicine | 2024 to 2025 | $291,181 | September 9, 2024 | July 31, 2027 | SONAWANE, KALYANI | reporter.nih.gov |
| Small Molecule E6 Inhibitors to Treat Oropharyngeal Cancers Caused by HPV Infections | NIH | National Institute of Dental & Craniofacial Research | 2022 | $275,766 | September 1, 2022 | August 31, 2024 | LU, ZHIJIAN | reporter.nih.gov |
| Integrating social and molecular determinants of HPV-associated cancers | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $265,990 | April 6, 2020 | February 28, 2023 | MAZUL, ANGELA LIU | reporter.nih.gov |
| IMAT-ITCR Collaboration: Development of a high-resolution mapping platform for HPV DNA integration in premalignant lesions | NIH | National Cancer Institute | 2021 | $265,613 | September 16, 2019 | August 31, 2023 | LENZ, JACK R. | reporter.nih.gov |
| Mali-Northwestern University Breast Cancer Prevention Research Training Program (MN-BCP) | NIH | Fogarty International Center | 2025 | $251,388 | August 25, 2025 | May 31, 2030 | DIAKITE, BREHIMA | reporter.nih.gov |
| Developing and evaluating a mobile application-based intervention to support HPV-tested women and increase their retention to follow-up: a mixed-methods implementation study | NIH | National Cancer Institute | 2023 | $246,493 | September 22, 2023 | August 31, 2025 | ARROSSI, SILVINA | reporter.nih.gov |
| Establishment of basal epithelial identity by papillomavirus oncoproteins | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $243,750 | December 1, 2023 | October 31, 2024 | WHITE, ELIZABETH A | reporter.nih.gov |
| Overcoming barriers to cancer screening among women living in rural and segregated communities | NIH | National Cancer Institute | 2021 to 2022 | $239,476 | September 1, 2019 | August 31, 2023 | MOSS, JENNIFER LINDSAY | reporter.nih.gov |
| Stories to Prevent (StoP) HPV Cancers: A communication intervention to increase HPV vaccination among diverse populations | NIH | National Cancer Institute | 2025 | $233,411 | April 1, 2025 | March 31, 2027 | CALO, WILLIAM ALEXIS | reporter.nih.gov |
| Mechanism of Dynein-mediated Early Intracellular Trafficking of Human Papillomavirus | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $230,250 | August 12, 2025 | July 31, 2027 | ZHANG, PENGWEI | reporter.nih.gov |
| Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccine | NIH | National Cancer Institute | 2021 | $229,659 | March 1, 2020 | February 28, 2023 | HUNG, CHIEN-FU | reporter.nih.gov |
| A Multilevel Social Capital Approach to Address Cervical Cancer Screening and Follow Up Delays among Latinas in Safety-Net Settings | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $225,721 | July 3, 2024 | January 31, 2026 | GARCIA, SAMANTHA | reporter.nih.gov |
| Germline risk of oral and oropharyngeal cancers across diverse populations | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $221,817 | August 1, 2021 | July 31, 2024 | VIRANI, SHAMA | reporter.nih.gov |
| Rewiring of epigenetic DNA damage response pathways in HPV-induced cancer | NIH | National Cancer Institute | 2021 | $219,209 | July 1, 2021 | February 28, 2022 | GOLDSTEIN, MICHAEL | reporter.nih.gov |
| Pilot of a network-driven, advocacy intervention to promote cervical cancer screening in Uganda | NIH | Fogarty International Center | 2021 | $212,571 | August 24, 2020 | April 30, 2023 | WANYENZE, RHODA KITTI | reporter.nih.gov |
| Developing and evaluating a mobile application-based intervention to support HPV-tested women and increase their retention to follow-up: a mixed-methods implementation study | NIH | National Cancer Institute | 2025 | $209,589 | September 22, 2023 | August 31, 2028 | ARROSSI, SILVINA | reporter.nih.gov |
| Targeting HPV Consequences in a Cervical Cancer Clinical Trial | NIH | National Cancer Institute | 2021 | $204,490 | June 1, 2016 | May 31, 2022 | BENBROOK, DORIS MANGIARACINA | reporter.nih.gov |
| Botswana-UPenn: Research Consortium of HPV-Related Cervical Cancer in HIV Patient | NIH | National Cancer Institute | 2023 | $203,207 | May 1, 2023 | July 31, 2023 | ROBERTSON, ERLE S. | reporter.nih.gov |
| Evaluating the adoption, implementation, and maintenance of a cervical precancer treatment in El Salvador | NIH | National Cancer Institute | 2025 | $202,487 | September 11, 2025 | August 31, 2027 | SOLER, MONTSERRAT | reporter.nih.gov |
| Establishment of basal epithelial identity by papillomavirus oncoproteins | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $200,063 | December 1, 2023 | October 31, 2026 | WHITE, ELIZABETH A | reporter.nih.gov |
| Proteolytic Regulation of HPV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $197,894 | April 1, 2020 | March 31, 2024 | IZAGUIRRE, GONZALO | reporter.nih.gov |
| Global Breast and Cervical Cancer Control: Implementing a Bundled Screening Approach in a Resource Limited Setting | NIH | National Cancer Institute | 2025 | $192,780 | March 1, 2025 | February 28, 2030 | GUTNIK, LILY | reporter.nih.gov |
| Randomized controlled trial of an implementation science tool to increase cervical cancer screening in Mombasa, Kenya | NIH | National Cancer Institute | 2021 to 2022 | $188,892 | July 6, 2018 | December 31, 2023 | EASTMENT, MCKENNA CLAIRE | reporter.nih.gov |
| Vaginal Microbiome in Cervical Intraepithelial Neoplasia and Cancer | NIH | Fogarty International Center | 2021 to 2022 | $185,976 | September 25, 2019 | April 30, 2024 | MUSA, JONAH | reporter.nih.gov |
| Pan-cancer genomic characterization of human papillomavirus associated tumors | NIH | National Cancer Institute | 2022 to 2025 | $185,946 | May 1, 2022 | April 30, 2026 | HOLT, JEREMIAH R. | reporter.nih.gov |
| HPV and HPV-related cancer prevention prevalence among people experiencing homelessness in the United States, 2006-2018 | NIH | National Cancer Institute | 2025 | $170,409 | August 1, 2025 | July 31, 2027 | GALVIN, ANNALYNN MAGUDDAYAO | reporter.nih.gov |
| The effect of epigenetic DNA methylation on the progression of HPV-associated precancerous cervical lesions | NIH | National Cancer Institute | 2021 to 2024 | $170,347 | February 1, 2021 | June 30, 2026 | BUKOWSKI, ALEXANDRA | reporter.nih.gov |
| The role of HPV E1 in regulating the NRF2-KEAP1 pathway | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $168,500 | January 19, 2023 | December 31, 2024 | BINNING, JENNIFER | reporter.nih.gov |
| mHealth delivered narrative intervention to increase cervical cancer screening among Malawian Women living with HIV | NIH | National Institute of Nursing Research | 2021 | $167,919 | April 23, 2020 | August 31, 2022 | LEE, HAEOK | reporter.nih.gov |
| Low-cost integrated nucleic acid amplification testing platform for cervical cancer screening in low- and middle-income countries | NIH | National Cancer Institute | 2023 to 2025 | $167,544 | June 1, 2023 | August 31, 2026 | MAKER, YAJUR NAMAN | reporter.nih.gov |
| Training to Prevent Anal Cancer (TPAC) | NIH | National Cancer Institute | 2025 | $165,271 | August 26, 2025 | July 31, 2027 | FLOWERS, LISA C. | reporter.nih.gov |
| Implementation of Inpatient Postpartum Human Papillomavirus Immunization | NIH | National Cancer Institute | 2021 | $165,013 | July 11, 2018 | June 30, 2023 | SHETH, SANGINI S. | reporter.nih.gov |
| Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina | NIH | National Institute on Minority Health and Health Disparities | 2025 | $165,012 | September 14, 2025 | March 31, 2029 | MANSFIELD, LISA NICOLE | reporter.nih.gov |
| Identifying modifiable multi-level factors associated with HPV vaccine uptake in Kenya and Malawi | NIH | National Cancer Institute | 2022 | $163,500 | September 19, 2022 | August 31, 2023 | MOUCHERAUD, CORRINA | reporter.nih.gov |
| Evaluating the impact of Basic needs Assessment and Support to Improve Colposcopy Show rate: The BASICS Trial | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $156,500 | July 1, 2022 | June 30, 2025 | KUROKI, LINDSAY M | reporter.nih.gov |
| Super-resolution mobile microscopy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $153,000 | August 1, 2025 | July 31, 2027 | LU, JIAN-YU | reporter.nih.gov |
| Point of Care Diagnostics of HPV-Associated Cervical Cancer in HIV Epidemic Areas in China | NIH | National Cancer Institute | 2021 | $150,036 | January 19, 2017 | December 31, 2022 | LIU, CHANGCHUN | reporter.nih.gov |
| An integrated community-clinic model of optimized implementation strategies to increase early detection of breast and cervical cancers in Kenya | NIH | National Cancer Institute | 2023 | $145,983 | February 1, 2023 | July 31, 2023 | SUBRAMANIAN, SUJHA | reporter.nih.gov |
| An implementation science approach to address multi-level barriers to cancer screening among women living with HIV in South Africa | NIH | Fogarty International Center | 2021 | $145,638 | August 14, 2020 | June 30, 2023 | CHIBWESHA, CARLA J | reporter.nih.gov |
| The Role of Sex-Hormones in Anal Human Papilloma Virus Persistence (HPV) and Systemic and Mucosal Immunity in people with or at risk for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $140,740 | September 12, 2025 | August 31, 2030 | HARFOUCH, OMAR | reporter.nih.gov |
| Understanding the Roles of the E6 and E7 Oncoproteins in MmuPV1 Induced Carcinogenesis | NIH | National Cancer Institute | 2021 to 2022 | $133,576 | July 1, 2020 | June 30, 2023 | ROMERO-MASTERS, JAMES | reporter.nih.gov |
| A Novel Strategy to Identify Protective T cell Epitopes for HPV Therapeutic Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $131,166 | August 1, 2025 | July 31, 2027 | GAO, FEI | reporter.nih.gov |
| Toward an improved screening protocol: developing and testing an organ inventory for strengthening clinical care and research | NIH | National Cancer Institute | 2021 | $129,778 | September 22, 2020 | March 31, 2023 | MOSESON LIDOW, HEIDI SERENE | reporter.nih.gov |
| Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $126,371 | February 1, 2019 | February 28, 2024 | RICCIO, DANIEL | reporter.nih.gov |
| Elucidating the role of dynein-cargo adaptor proteins in Human papillomavirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $123,990 | September 1, 2022 | August 31, 2025 | SPECKHART, KAITLYN NOEL | reporter.nih.gov |
| Integrating social and molecular determinants of HPV-associated cancers | NIH | National Institute on Minority Health and Health Disparities | 2023 | $123,323 | April 6, 2020 | June 30, 2025 | MAZUL, ANGELA LIU | reporter.nih.gov |
| Harnessing Big Data to Identify Geographic Clusters of Low-income children with Poor HPV Vaccination Rates | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $120,922 | September 1, 2021 | August 8, 2022 | SONAWANE, KALYANI | reporter.nih.gov |
| Point-of-care optical imaging to provide real-time histology to enable screening for cervical cancer and its precursors | NIH | National Cancer Institute | 2021 | $105,299 | September 21, 2016 | November 30, 2022 | KEAHEY, PELHAM | reporter.nih.gov |
| Evaluating the Influence of Culture and Risk Perception on HPV Vaccination Intention among Haitian Immigrant Women Living with HIV | NIH | National Institute of Nursing Research | 2023 to 2024 | $98,146 | May 23, 2023 | March 31, 2025 | GUILLAUME, DOMINIQUE GISELE | reporter.nih.gov |
| Investigating novel host factors promoting human papillomavirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $96,839 | January 1, 2021 | April 30, 2023 | HARWOOD, MARA CALYPSO | reporter.nih.gov |
| Development of a Physiologically Replete Cervix Model with Three-Dimensional Cellular Co-Culture for the Evaluation of High-Risk Human Papillomavirus and Cervical Cancer Biomarkers | NIH | National Cancer Institute | 2025 | $93,047 | September 1, 2024 | August 31, 2029 | NOVAK, EMILIE NEWSHAM | reporter.nih.gov |
| Economic evaluation of strategies to address the significant cervical cancer burden in Malawi | NIH | National Cancer Institute | 2021 | $79,493 | December 16, 2019 | November 30, 2022 | MOUCHERAUD, CORRINA | reporter.nih.gov |
| The role of ERBB2 signaling in HPV-induced pathologies | NIH | National Cancer Institute | 2024 | $76,514 | July 1, 2024 | June 30, 2025 | RIVERA-CRUZ, COSETTE M | reporter.nih.gov |
| Innovative Rapid Enabling, Affordable, point-of-Care HPV Self-Testing Strategy (I-REACH) | NIH | National Cancer Institute | 2023 | $58,583 | September 1, 2023 | September 2, 2023 | IWELUNMOR, JULIET | reporter.nih.gov |
| An Automated Multimodal, Multiscale Algorithm for Cervical Cancer Screening in Low- and Middle-Income Countries | NIH | National Cancer Institute | 2025 | $52,139 | August 1, 2025 | June 30, 2026 | GOLI, KARTHIK | reporter.nih.gov |
| Human papillomavirus mRNA detection for assessing cervical cancer risk in resource-limited settings | NIH | National Cancer Institute | 2024 | $50,474 | September 1, 2024 | August 31, 2026 | NOVAK, EMILIE NEWSHAM | reporter.nih.gov |
| Individual, Interpersonal, and Community Factors Associated with HPV Vaccine Hesitancy among Mexican American Young Adult Women | NIH | National Institute on Minority Health and Health Disparities | 2021 | $46,036 | September 1, 2020 | August 31, 2022 | GARCIA, SAMANTHA | reporter.nih.gov |
| Investigating the mechanism by which PTPN14 degradation by HPV E7 represses epithelial differentiation | NIH | National Institute of Dental & Craniofacial Research | 2021 | $42,099 | September 1, 2020 | June 24, 2022 | HATTERSCHIDE, JOSHUA | reporter.nih.gov |
| Implementation Penetration Assessment Criteria Tool for HPV Vaccination- Promoting Uptake among Young Girls in Nigeria | NIH | National Cancer Institute | 2024 | $36,801 | February 5, 2025 | February 4, 2027 | ANIKAMADU, ONYEKACHUKWU | reporter.nih.gov |
| Cervical cancer in Botswana: Identifying demographic, clinical and geographical features | NIH | National Cancer Institute | 2021 | $29,947 | March 1, 2021 | August 15, 2021 | FRIEBEL-KLINGNER, TARA MARIE | reporter.nih.gov |
| SUPPORT FOR HPV16L1/RG1 CHIMERIC VIRUS-LIKE PARTICLE VACCINE CLINICAL DEVELOPMENT TASKS 1&2 | NIH | National Cancer Institute | 2021 | $28,823 | September 25, 2015 | March 31, 2021 | LYUBIMOV, ALEXANDER | reporter.nih.gov |
| Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation | NIH | National Cancer Institute | 2023 | $23,201 | July 1, 2023 | September 5, 2023 | ZAMARIN, DMITRIY | reporter.nih.gov |
| Rapid Point of Care Test to Screen Human Papillomavirus in Low-Resource Settings | NIH | National Cancer Institute | 2023 | $13,720 | August 7, 2023 | August 6, 2024 | LI, QIAN | reporter.nih.gov |
| Vietnamese-American parents' HPV vaccine uptake for their adolescent children: An examination of practice-, provider-, and patient-level influences | NIH | National Cancer Institute | 2021 | $4,938 | July 22, 2019 | August 31, 2021 | VU, HA NGAN | reporter.nih.gov |
| Factors Associated with Mailed Return of Self-Sampling for Human Papillomavirus (HPV) Testing | NIH | National Institute of Nursing Research | 2021 | $2,500 | September 1, 2019 | August 31, 2021 | BIEDERMAN, ERIKA | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 2 | $77.7 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 3 | $44.9 million | 0 | $0 |
| Fundacion Inciensa | San Jose | 2 | $32.6 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 3 | $31.5 million | 0 | $0 |
| University of California at Davis | Davis, CA | 2 | $18.5 million | 0 | $0 |
| Universitat Bern | Bern | 1 | $16.8 million | 0 | $0 |
| Washington University | Saint Louis, MO | 16 | $16.2 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 5 | $13.7 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 7 | $12.1 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 8 | $11.1 million | 0 | $0 |
| University of Washington | Seattle, WA | 8 | $10.7 million | 0 | $0 |
| Emory University | Atlanta, GA | 7 | $8.9 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 5 | $8.9 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 9 | $8.6 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 9 | $8.3 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 3 | $7.9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 4 | $7.8 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 6 | $7.6 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 8 | $7.4 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 2 | $7.4 million | 0 | $0 |
| Duke University | Durham, NC | 6 | $6.2 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 5 | $6.1 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 4 | $5.6 million | 0 | $0 |
| Tufts Medical Center | Boston, MA | 2 | $5.3 million | 0 | $0 |
| Frontier Sci & Technology RSCH FDN, INC | Amherst, NY | 1 | $5.3 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 4 | $5.2 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 3 | $5 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 2 | $4.9 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 3 | $4.9 million | 0 | $0 |
| Lifegene-Biomarks, Inc. | San Juan, PR | 3 | $4.9 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 3 | $4.7 million | 0 | $0 |
| International Agency for Res on Cancer | Lyon | 4 | $4.3 million | 0 | $0 |
| Calla Health Foundation | Durham, NC | 3 | $4.1 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 3 | $4.1 million | 0 | $0 |
| William Marsh Rice University | Houston, TX | 6 | $4 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 3 | $3.9 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 1 | $3.6 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 3 | $3.5 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 4 | $3.3 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 2 | $3.1 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 4 | $2.9 million | 0 | $0 |
| New York University | New York, NY | 3 | $2.9 million | 0 | $0 |
| Kovina Therapeutics Inc. | Indianapolis, IN | 4 | $2.9 million | 0 | $0 |
| Comprehensive Cancer Center/ Univ/pr | San Juan, PR | 2 | $2.9 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 3 | $2.9 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 4 | $2.8 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 5 | $2.8 million | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 2 | $2.8 million | 0 | $0 |
| Ananya Health INC | Oakland, CA | 2 | $2.7 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 3 | $2.6 million | 0 | $0 |
| Pensievision, Inc. | San Diego, CA | 2 | $2.6 million | 0 | $0 |
| University of Rochester | Rochester, NY | 2 | $2.5 million | 0 | $0 |
| Tufts University | Medford, MA | 1 | $2.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 2 | $2.4 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 3 | $2.4 million | 0 | $0 |
| Veloxai LLC | Austin, TX | 2 | $2.4 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 3 | $2.4 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 3 | $2.3 million | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 2 | $2.3 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 3 | $2.1 million | 0 | $0 |
| Privo Technologies, LLC | Peabody, MA | 1 | $2 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 2 | $2 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 1 | $2 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 3 | $2 million | 0 | $0 |
| Rand Corporation | Santa Monica, CA | 1 | $2 million | 0 | $0 |
| Atila Biosystems, Inc. | Sunnyvale, CA | 1 | $2 million | 0 | $0 |
| DL Analytics, LLC | North Hollywood, CA | 1 | $2 million | 0 | $0 |
| Crosslife Technologies, Inc. | Carlsbad, CA | 1 | $2 million | 0 | $0 |
| Implenomics LLCS | Marblehead, MA | 2 | $1.9 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 2 | $1.9 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 2 | $1.9 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 1 | $1.9 million | 0 | $0 |
| Isa Associates, Inc. | Arlington, VA | 1 | $1.9 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 2 | $1.8 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 1 | $1.8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 1 | $1.7 million | 0 | $0 |
| Teal Health INC | San Francisco, CA | 1 | $1.6 million | 0 | $0 |
| Glyciome, LLC | Valleyford, WA | 2 | $1.5 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 2 | $1.4 million | 0 | $0 |
| Baylor University | Waco, TX | 2 | $1.4 million | 0 | $0 |
| University College London | London | 1 | $1.3 million | 0 | $0 |
| University of Cape Town | Rondebosch | 1 | $1.3 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 1 | $1.3 million | 0 | $0 |
| University of South Dakota Main Campus | Vermillion, SD | 1 | $1.2 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 1 | $1.2 million | 0 | $0 |
| Basic Health International, Inc. | Pittsburgh, PA | 1 | $1.1 million | 0 | $0 |
| Louisiana State Univ HSC Shreveport | Shreveport, LA | 1 | $1.1 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 2 | $1.1 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 2 | $1 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 1 | $1 million | 0 | $0 |
| Dare Bioscience, Inc. | San Diego, CA | 1 | $1 million | 0 | $0 |
| Nanocan Therapeutics Corporation | Princeton, NJ | 1 | $998,781 | 0 | $0 |
| George Washington University | Washington, DC | 2 | $957,586 | 0 | $0 |
| University of Virginia | Charlottesville, VA | 2 | $935,870 | 0 | $0 |
| Research for Development | Kigali | 1 | $928,400 | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 2 | $925,679 | 0 | $0 |
| Brown University | Providence, RI | 1 | $893,812 | 0 | $0 |
| Information Management Services, Inc. | Calverton, MD | 1 | $887,000 | 0 | $0 |
| Makerere University Walter Reed Program Limited | Kampala | 1 | $858,136 | 0 | $0 |
| Pharmajet, Inc. | Golden, CO | 1 | $843,564 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 170 | $107,524,504 | 0 | $0 |
| 2024 | 185 | $124,898,508 | 0 | $0 |
| 2023 | 188 | $129,999,352 | 0 | $0 |
| 2022 | 168 | $122,427,161 | 0 | $0 |
| 2021 | 127 | $97,056,567 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.